VBI Vaccines (NASDAQ:VBIV) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of VBI Vaccines (NASDAQ:VBIV) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “

Several other brokerages also recently commented on VBIV. ValuEngine raised VBI Vaccines from a hold rating to a buy rating in a research note on Thursday, August 1st. BMO Capital Markets lowered their target price on VBI Vaccines to $5.00 and set an outperform rating for the company in a research note on Tuesday, June 18th. Finally, Oppenheimer set a $5.00 target price on VBI Vaccines and gave the stock a buy rating in a research note on Wednesday, June 19th.

Shares of NASDAQ VBIV opened at $0.62 on Wednesday. The company has a current ratio of 0.95, a quick ratio of 0.92 and a debt-to-equity ratio of 0.01. The company has a market cap of $59.58 million, a price-to-earnings ratio of -0.64 and a beta of 0.41. VBI Vaccines has a 12 month low of $0.57 and a 12 month high of $2.78. The stock has a 50-day moving average price of $0.75 and a two-hundred day moving average price of $1.54.

VBI Vaccines (NASDAQ:VBIV) last issued its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. The firm had revenue of $0.64 million during the quarter, compared to the consensus estimate of $0.60 million. VBI Vaccines had a negative return on equity of 73.80% and a negative net margin of 1,582.45%. On average, sell-side analysts predict that VBI Vaccines will post -0.46 earnings per share for the current year.

In other news, major shareholder Life Sciences Maste Perceptive acquired 1,000,000 shares of the stock in a transaction dated Monday, June 17th. The stock was bought at an average price of $0.62 per share, with a total value of $620,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeff Baxter acquired 144,000 shares of the stock in a transaction dated Wednesday, June 19th. The stock was purchased at an average cost of $0.73 per share, with a total value of $105,120.00. Following the purchase, the chief executive officer now directly owns 458,255 shares of the company’s stock, valued at $334,526.15. The disclosure for this purchase can be found here. Insiders bought 1,160,000 shares of company stock valued at $739,600 in the last ninety days. 10.50% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Weil Company Inc. acquired a new position in shares of VBI Vaccines in the first quarter valued at approximately $41,000. JPMorgan Chase & Co. acquired a new position in shares of VBI Vaccines in the second quarter valued at approximately $25,000. Citadel Advisors LLC acquired a new position in shares of VBI Vaccines in the second quarter valued at approximately $31,000. Bank of New York Mellon Corp acquired a new position in shares of VBI Vaccines in the fourth quarter valued at approximately $51,000. Finally, Bank of Montreal Can increased its stake in shares of VBI Vaccines by 71.8% in the second quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 15,717 shares during the period. 51.12% of the stock is owned by institutional investors.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Further Reading: What is intrinsic value?

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.